The Latest Cardiac and Vascular News
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2024 financial results. “We are proud to announce a strong start to 2024, marked by growth across each of our […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights. Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity Post this “2024 is off to a […]
CARLSBAD, Calif., May 2, 2024 /PRNewswire/ — MedRes International, Inc. is pleased to announce the opening of its new technology development center in Carlsbad, California, in May 2024. The Carlsbad site is equipped to accelerate customer projects in the fields of cardiovascular…
WINTER SPRINGS, Fla., May 02, 2024 (GLOBE NEWSWIRE) — IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three months ended March 31, 2024. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
– Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTRibute-CM Phase 3 study of acoramidis at the American College of Cardiology Annual Scientific Sessions; additional detailed results from ATTRibute-CM are planned for presentation at 2024 medical meetings, including four abstracts accepted for the European Society of Cardiology Heart Failure conference and eleven abstracts accepted for the International Symposium on Amyloidosis in May 2024
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2024, and updated financial guidance for its fiscal year ending September 30, 2024. “I’m incredibly proud of […]
Caesarea, Israel – April 30, 2024 – Arineta, a leader in advancing cardiovascular imaging solutions through cutting-edge technology, is announcing its partnership with Shandong Yituo Medical Technology Development Co. Ltd. (SYMT), a JMC-invested company. Its new joint venture company, Arineta (Shandong) Medical Equipment Co. Ltd., is anticipating the installation of […]
Award supports design and preclinical testing of Pulmonary Flow Restrictor for Congenital Heart Disease SAN DIEGO, May 1, 2024 /PRNewswire/ — Starlight Cardiovascular, Inc., a company developing pediatric cardiovascular medical devices, announced that it has been awarded a Small Business…
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2024.
IRVINE, Calif., April 30, 2024 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2024.
